WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999038513) R-LANSOPRAZOLE COMPOSITIONS AND METHODS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/038513    International Application No.:    PCT/US1999/001938
Publication Date: 05.08.1999 International Filing Date: 29.01.1999
Chapter 2 Demand Filed:    30.08.1999    
IPC:
A61K 31/4439 (2006.01)
Applicants: SEPRACOR INC. [US/US]; 111 Locke Drive Marlborough, MA 01752 (US)
Inventors: BARBERICH, Timothy, J.; (US).
YELLE, William, E.; (US).
RUBIN, Paul, D.; (US)
Agent: HANSEN, Philip, E.; Heslin & Rothenberg, P.C. 5 Columbia Circle Albany, NY 12203 (US)
Priority Data:
60/073,140 30.01.1998 US
Title (EN) R-LANSOPRAZOLE COMPOSITIONS AND METHODS
(FR) COMPOSITIONS ET PROCEDES D'UTILISATION DU R-LANSOPRAZOLE
Abstract: front page image
(EN)Methods and compositions are disclosed utilizing optically pure (+) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) lansoprazole is an inhibitor of H?+¿ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
(FR)La présente invention concerne des compositions et des procédés d'utilisation du (+)-lansoprazole optiquement pur permettant le traitement d'ulcères chez l'homme, tout en réduisant notablement le risque concomitant d'effets secondaires associés à l'utilisation du mélange racémique de lansoprazole. L'isomère (+) optiquement pur est aussi utile dans le traitement des reflux gastro-oesophagiens. Comme le (+)-lansoprazole est un inhibiteur de libération d'H?+¿, il permet de traiter d'autres troubles liés à l'hypersécrétion gastrique, tels que le syndrome de Zollinger-Ellison.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)